NYSE : PFE

Pfizer Inc.

$24.54 USD

-$0.47 (-1.88%)

Volume
22.86M
Average Volume
41.23M
Market Capitalization
$139.86B
P/E Ratio
18.73
Dividend Yield
7.01%
Price Target
$27.00
Year High
$28.75
Year Low
$23.11
Day High
—
Day Low
—
Payout Ratio
$1.31
Current Ratio
$1.25
Company Overview

NYSE

Albert Bourla

Drug Manufacturers - General

Healthcare

PFE

75000

US

USD

https://www.pfizer.com

212 733 2323

717081103

0000078003

Liquidity Metrics

0.72

1.25

0.94

0.05

1.31

Sales & Valuation

$62.58B

2.21

1.55

14.75

1.67

Profitability

$1.36

$7.77B

11.83%

12.49%

8.37%

3.61%

P/E Metrics

18.73

-3.25

-3.25

Analyst Price Target & Rating

$27.00

$30.00

$25.00

Neutral

3/5

39 Analysts

-9.11%

Financial Health Scores

2.04

5/9

$8.47B

$207.62B

$117.21B

$10.59B

Key Metrics (TTM)

$202.62B

3.20

12.10

1.25

8.37%

7.97%

5.36%

6.78%

$21.65

188 days

Company Executives
Name Title
Payal Sahni Becher Chief People Experience Officer & Executive Vice President
Aamir Malik Executive Vice President & Chief U.S. Commercial Officer
Douglas Lankler Executive Vice President & Chief Legal Officer
Francesca DeMartino Chief Investor Relations Officer
Dennis Hancock Executive VP & Chief Information Officer
David Denton Executive Vice President & Chief Financial Officer
Jennifer Damico Senior Vice President, Controller & Principal Accounting Officer
Albert Bourla Chairman of the Board & Chief Executive Officer
Chris Boshoff FMedSci Chief Scientific Officer and President of Research & Development
Michael S. Vincent Senior Vice President and Chief Scientific Officer of Inflammation & Immunology
Poll Results

No votes yet today — be the first to share your view!

About Pfizer Inc. (NYSE:PFE) Stock

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal dis ... ease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried.

2026-07-25 08:15:00

Pfizer is a large and well-respected pharmaceutical company. Pfizer has been facing headwinds, leaving investors worried about the dividend.

Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer

2026-07-23 17:00:00

Pfizer's payout ratio looks far too high. However, the company's dividend has increased despite headwinds in recent years.

PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use

2026-07-23 12:56:05

Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.

Verizon Was Booted From the Dow – 5 Dividend Giants Got the Same Treatment and Eventually Soared

2026-07-23 08:13:31

Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and steady income streams that index investors missed out on entirely.

Pfizer Inc. $PFE Shares Purchased by ABN Amro Investment Solutions

2026-07-23 03:47:07

ABN Amro Investment Solutions lifted its holdings in shares of Pfizer Inc. (NYSE: PFE) by 11.9% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 313,794 shares of the biopharmaceutical company's stock after purchasing an additional 33,262 shares during the quarter. ABN Amro

Pfizer's prostate cancer drug combination gets US FDA priority review

2026-07-22 16:48:21

Pfizer said on Wednesday the U.S. ​Food and Drug Administration has ‌granted priority review to its application seeking expanded approval for its prostate ​cancer treatment combination.

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

2026-07-22 16:30:00

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC), also known as meta.

2 Absurdly Cheap Healthcare Stocks to Buy Before July Ends

2026-07-22 08:00:21

Healthcare is quietly becoming the value hunter's playground of 2026. While the mega cap tech trade keeps sucking up oxygen, two of the largest healthcare names in the S&P 500 are trading at forward multiples that look mispriced against their earnings power.

Frequently Asked Questions

What is the current Pfizer Inc. (PFE) stock price?

Pfizer Inc.(NYSE:PFE) stock price is $24.54 in the last trading session. During the trading session, PFE stock reached the peak price of $28.75 while $23.11 was the lowest point it dropped to. The percentage change in PFE stock occurred in the recent session was --1.88% while the dollar amount for the price change in PFE stock was -$0.47.

PFE's industry and sector of operation?

The NYSE listed PFE is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of PFE?

Payal Sahni Becher | Chief People Experience Officer & Executive Vice President
Aamir Malik | Executive Vice President & Chief U.S. Commercial Officer
Douglas Lankler | Executive Vice President & Chief Legal Officer
Francesca DeMartino | Chief Investor Relations Officer
Dennis Hancock | Executive VP & Chief Information Officer

How many employees does PFE have?

Number of PFE employees currently stands at 75000. PFE operates from 66 Hudson Boulevard East, New York City, NY 10001-2192, US.

Link for PFE official website?

Official Website of PFE is: https://www.pfizer.com

How do I contact PFE?

PFE could be contacted at phone #212 733 2323 and can also be accessed through its website. PFE operates from 66 Hudson Boulevard East, New York City, NY 10001-2192, US.

How many shares of PFE are traded daily?

The average number of PFE shares traded daily for last 3 months was 41.23M.

What is the market cap of PFE currently?

The market value of PFE currently stands at $139.86B with its latest stock price at $24.54